Companies · Biotechnology
Pembroke · Biotechnology
Diligence memoA one-page analyst read on C-Reveal Therapeutics Llc — recommendation, valuation, rhythm, risks.→C-Reveal Therapeutics Llc looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
C-Reveal Therapeutics Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
C-Reveal Therapeutics Llc is one of 4293 Biotechnology companies tracked from Pembroke. By capital raised it ranks in the long tail (ahead of 35% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 35% of sector peers (real $). Modeled value above 61% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #28 of 186.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Novo Biosciences, Inc. | Seed | $4.0M | $177.6M | 2.76× |
| Entac Medical, Inc. | Seed | $4.0M | $177.6M | 2.76× |
| ReGelTec, Inc. | Seed | $6.0M | $177.6M | 2.76× |
| Korro Bio, Inc. | Seed | $4.0M | $177.6M | 2.76× |
| TamuroBio Inc. | Seed | $4.0M | $177.6M | 2.76× |
| Initial Therapeutics, Inc. | Seed | $3.8M | $168.6M | 2.62× |
| Helaina Inc | Seed | $4.4M | $165.0M | 2.57× |
| Onchilles Pharma, Inc. | Seed | $3.6M | $158.5M | 2.47× |
| UVision 360, Inc. | Seed | $4.6M | $155.7M | 2.42× |
| Safeguard Biosystems Holdings Ltd | Seed | $3.5M | $155.4M | 2.42× |
| Enable Medicine Inc. | Seed | $3.6M | $152.3M | 2.37× |
| Newomics Inc. | Seed | $3.9M | $149.0M | 2.32× |
| C-Reveal Therapeutics Llc this company | Seed | $3.3M | $111.6M | 1.74× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.3M | 2020-12-18 | $16.3M | $111.6M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Keith Flaherty | — | 4 other | 2020-12 |
| Mark Cobbold | — | 1 other | 2020-12 |
| Cyril Benes | — | — | 2020-12 |
| Thomas Haag | — | — | 2020-12 |
C-Reveal Therapeutics Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Canopy Biosciences, LLC | Biotechnology | Seed | $3.2M | $92.1M | same sector · same stage |
| CAMBRIDGE SCIENCE Corp | Biotechnology | Seed | $3.2M | $98.3M | same sector · same stage |
| Kit Company, Inc. | Biotechnology | Seed | $3.3M | $119.8M | same sector · same stage |
| Sharklet Technologies, Inc. | Biotechnology | Seed | $3.2M | $89.0M | same sector · same stage |
| Neoantigenics, Inc. | Biotechnology | Seed | $3.1M | $134.4M | same sector · same stage |
| Stellar Biotechnologies Inc. | Biotechnology | Seed | $3.4M | $123.6M | same sector · same stage |
| Silicon Kinetics Inc | Biotechnology | Seed | $3.1M | $127.6M | same sector · same stage |
| Moleculera Labs, Inc. | Biotechnology | Seed | $3.4M | $131.4M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Stealth Therapeutics, Inc. | Biotechnology | Seed | $6.2M | 85% |
| Reveal Biosensors, Inc. | Biotechnology | Pre-Seed | $12.4M | 84% |
| Stealth BioTherapeutics Corp | Biotechnology | Series B | $793.8M | 82% |
| RevOpsis Therapeutics, Inc. | Biotechnology | Series A | $2.6M | 81% |
| RevOpsis Therapeutics Corp | Biotechnology | Pre-Seed | $9.9M | 81% |
| ConformationX Therapeutics LLC | Biotechnology | Series A | $166.3M | 81% |
| Cessation Therapeutics, Inc. | Biotechnology | Series A | $5.9M | 80% |
| PEEL Therapeutics, Inc | Biotechnology | Series A | $334.5M | 79% |
See where C-Reveal Therapeutics Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at C-Reveal Therapeutics Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.